NICE approves use of trastuzumab deruxtecan for advanced breast cancer via the Cancer Drugs Fund

Written by Louis Gautier, Future Science Group

trastuzumab deruxtecan

The National Institute for Health and Care Excellence (NICE) recently published draft guidance recommending trastuzumab deruxtecan, also known as Enhertu, for HER2-positive, unresectable or metastatic breast cancer, following two lines of prior anti-HER2 therapy. The drug will be available via the Cancer Drugs Fund. NICE’s approval is based on clinical data from a single arm of the open-label, international, multicenter, Phase II DESTINY-Breast01 trial (NCT03248492), in which trastuzumab deruxtecan demonstrated durable anticancer activity in HER2-positive, unresectable or metastatic breast cancer who’d received two prior lines of anti-HER2 therapy [1]. First-line treatment for HER2-positive unresectable or metastatic breast cancer includes anti-HER2...

To view this content, please register now for access

It's completely free